Resistance to therapy caused by intragenic deletion in BRCA2 (Q28268169)

4

0 references

Alan Ashworth

9

0 references

Jorge Reis-Filho

8

Jorge S Reis-Filho

0 references

Christopher J Lord

Christopher J Lord

3

0 references

Rachel Brough

2

Rachel Brough

0 references

Radost Vatcheva

5

Radost Vatcheva

0 references

author name string

Stacey L Edwards

1

0 references

Douglas A Levine

6

0 references

Jeff Boyd

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7

0 references

language of work or name

English

0 references

publication date

28 February 2008

0 references

published in

Nature

0 references

volume

451

0 references

page(s)

1111-5

0 references

issue

7182

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

BRCA2 is required for homology-directed repair of chromosomal breaks

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Clinical management of BRCA1 and BRCA2 mutation carriers

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

BRCA2 regulates homologous recombination in response to DNA damage: implications for genome stability and carcinogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

A model of oncogenic rearrangements: differences between chromosomal translocation mechanisms and simple double-strand break repair

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Suppression of the DNA repair defects of BRCA2-deficient cells with heterologous protein fusions

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Improved survival in women with BRCA-associated ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Improved survival in BRCA2 carriers with ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Cellular processing of platinum anticancer drugs

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

In vivo reversion to normal of inherited mutations in humans

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Sulforhodamine B colorimetric assay for cytotoxicity screening.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Calculating slope and ED50 of additive dose-response curves, and application of these tabulated parameter values.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021

Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FNATURE06548

7 January 2021